A distributed “hub-and-spoke” operation could register as one establishment, reducing administrative friction while improving ...

A new generation of therapies aims to intervene at a recently discovered gap between the disease’s molecular march and its ...

Scientists gave five people with mild Alzheimer’s disease daily doses of flickering light and pulsing sound therapy at 40 Hz ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in ...

Children as young as two with sickle cell disease can now receive a one-time CRISPR-based gene therapy after the FDA issued a ...

Madalyn Palencia’s grandmother works at Kaiser Permanente. Saniya Chandy volunteers with the Red Cross. Rebeca Bonilla has ...

Mice engineered to develop Alzheimer’s-like disease lost cognitive function faster when infected with a common herpesvirus, ...

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced ...

Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan.The study data will be used to support a New Drug Application (NDA) for ...

ERAS-0015 Phase 1 data, valuation gap, Merck deal, funding, and key risks like patents. Click for more on ERAS stock.

An independent investigation cannot undo what happened in Houston or Biddeford. But it can begin restoring confidence that ...

We’ve built global highways for approved medicines and left clinical trial access on something closer to dirt roads.